GNG12 regulates PD‐L1 expression by activating NF‐κB signaling in pancreatic ductal adenocarcinoma

• Main Authors: Juan Li, Can Jin, Chuanxin Zou, Xu Qiao, Peng Ma, Di Hu, Wenqin Li, Jun Jin, Xin Jin, Ping Fan
• Format: Article
• Language: English
• Published: Wiley 2020-02-01
• Series: FEBS Open Bio
• Subjects: GNG12; p65; pancreatic ductal adenocarcinoma; PD‐L1
• Online Access: https://doi.org/10.1002/2211-5463.12784

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid tumors in the digestive system. A greater understanding of the pathogenesis of PDAC may facilitate the search for new therapeutic targets. Guanine nucleotide‐binding protein subunit gamma‐12 (GNG12) belongs to the G protein family and participates in the modulation of the inflammatory signaling cascade. However, the cancer‐related function and clinical relevance of GNG12 in PDAC have not previously been reported. Here, we investigated the clinical significance of GNG12 in PDAC using the Oncomine web tool, the gene expression profiling interactive analysis tool and tissue microarray (TMA). GNG12 expression was observed to be higher in PDAC patient specimens than in nontumor pancreatic tissues, and high expression of GNG12 was associated with poor prognosis. We subsequently show that GNG12 promotes pancreatic cancer cell growth in vivo and in vitro, as evaluated using 3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐2H‐tetrazolium, inner salt assays, colony formation assays and a xenograft mouse model. Furthermore, our results suggest that GNG12 activates nuclear factor‐κB signaling and modulates the immune response. Collectively, our findings suggest that GNG12 may be suitable as a new prognosis‐related biomarker and a promising target for treatment of pancreatic cancer.